Is hs-CRP a marker of low-grade systemic inflammation and higher cardiovascular risk?

Clinical evidence

• Cardiovascular Risk Prediction: Evidence from large-scale prospective cohort studies and individual-participant meta-analyses confirms that high-sensitivity C-reactive protein (hs-CRP) is an independent risk-enhancing factor for atherosclerotic cardiovascular disease (ASCVD). In primary prevention settings, hs-CRP levels greater than 2.0 to 3.0 mg/L are associated with a 1.5- to 2.0-fold hazard increase for major cardiovascular events and vascular mortality compared to levels below 1.0 mg/L.
• Residual Inflammatory Risk: In patients who have already achieved low-density lipoprotein cholesterol (LDL-C) targets through statin therapy, elevated hs-CRP (typically $\ge 2.0$ mg/L) identifies individuals with high residual inflammatory risk. The joint evaluation of inflammatory markers and lipid profiles shows that individuals with simultaneous elevations of both hs-CRP and atherogenic markers like Apolipoprotein B (ApoB) or LDL-C experience the highest overall cardiovascular event rates.

Mechanistic explanations

• Cytokine-Driven Hepatic Synthesis: Systemic inflammation begins with upstream triggers that stimulate macrophages and other immune cells to release Interleukin-6 (IL-6).
• Transcriptional Activation: Circulating IL-6 acts directly on hepatocytes, binding to its receptor complex and activating the gp130-JAK-STAT3 signaling pathway. This pathway transcriptionally activates and stimulates the rapid synthesis and secretion of C-reactive protein (CRP) into the bloodstream.
• Assay Sensitivity: Standard CRP tests only detect high-grade inflammation (typically >10 mg/L) from acute infections or tissue injury. In contrast, hs-CRP assays utilize advanced analytical techniques to detect subclinical levels of circulating CRP down to 0.1 mg/L, making it a highly validated surrogate marker of chronic, low-grade systemic inflammation.

Bottom line

High-sensitivity C-reactive protein is a highly reliable clinical marker of low-grade systemic inflammation. Elevated hs-CRP levels exceeding 2.0 mg/L are strongly and independently associated with increased cardiovascular risk, serving as a critical indicator of residual inflammatory risk even in patients with well-controlled cholesterol levels.